Mabwell(SH:688062) ZHONGTAI SECURITIES·2026-02-25 10:30Investment Rating - The report assigns an "Outperform" rating for the company, indicating a positive outlook for its future performance [4]. Core Insights - The company is positioned as an innovative biopharmaceutical enterprise with a comprehensive industry chain layout and a clear direction for innovation, focusing on unmet clinical needs in oncology and aging-related diseases [2][9]. - The company has established a dual-driven innovation model through self-developed technologies and business development (BD) partnerships, enhancing its pipeline and market presence [2][4]. - The company is actively expanding its product offerings and entering new markets, with a focus on both domestic and international growth strategies [4][21]. Summary by Relevant Sections Company Overview - The company was founded in 2017 and went public on the Shanghai Stock Exchange in 2022, with plans for a Hong Kong listing to support its international expansion [9]. - The management team is experienced, with a stable shareholding structure, ensuring strategic decisions align with the company's core needs [11][13]. Research and Development - The company has multiple R&D platforms, including ADC, TCE, MyoDock™, and small nucleic acids, which work synergistically to achieve innovation and differentiation [22][23]. - The pipeline is rich, focusing on oncology for immediate returns while also developing anti-aging therapies for long-term growth [28]. Business Development Strategy - The company employs a diversified approach to business development, combining internal capabilities with external partnerships to maximize pipeline value [4][19]. - Collaborations with various partners, including local and global firms, are aimed at enhancing product commercialization and expanding market reach [4][21]. Financial Projections and Valuation - Revenue projections for 2025 to 2027 are estimated at 6.74 billion, 11.63 billion, and 12.73 billion RMB, respectively, indicating significant growth potential [4]. - The current market valuation is considered undervalued based on the company's projected cash flow and product pipeline [4]. Product Pipeline Highlights - The core product, Nectin-4 ADC (9MW2821), is in advanced clinical trials for multiple indications, including urothelial carcinoma and cervical cancer, with potential peak sales estimated at 1.988 billion RMB [31][33]. - The company is also developing innovative therapies for Alzheimer's disease and chronic obstructive pulmonary disease, showcasing its commitment to addressing critical health challenges [2][28].